Long-term Safety and Effectiveness of Rezafungin Treatment in Candidemia and Invasive Candidiasis: Results From an Early Access Program in Italy and Germany
Filippo Trapani, Giulio Viceconte, Valentina Morena, Giusy Tiseo, Giovanni Mori, Britta Kölking, Elham Khatamzas
Abstract
Abstract Outcomes are reported for 6 adults receiving rezafungin for chronic, hard-to-treat, invasive candidiasis (including Candida parapsilosis) during an early access program. Rezafungin was well tolerated and administered via once-weekly outpatient intravenous infusion for up to 39 weeks during the program, enabling hospital discharge and replacing daily antifungal infusions.
Topics & Concepts
MedicineInvasive candidiasisIntensive care medicineTerm (time)PediatricsAntifungalFluconazoleDermatologyPhysicsQuantum mechanicsAntifungal resistance and susceptibilityFungal Infections and StudiesCystic Fibrosis Research Advances